NYSE:TARO - Taro Pharmaceutical Industries Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$115.59 -1.91 (-1.63 %)
(As of 06/25/2018 03:13 PM ET)
Previous Close$116.41
Today's Range$115.59 - $117.04
52-Week Range$93.01 - $128.46
Volume1,245 shs
Average Volume57,657 shs
Market Capitalization$4.71 billion
P/E Ratio19.01
Dividend YieldN/A
Taro Pharmaceutical Industries logoTaro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Sun Pharmaceutical Industries Ltd.

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio8.79
Quick Ratio8.12


Trailing P/E Ratio19.01
Forward P/E Ratio11.95
P/E GrowthN/A

Sales & Book Value

Annual Sales$661.91 million
Price / Sales7.00
Cash Flow$6.4865 per share
Price / Cash17.82
Book Value$55.12 per share
Price / Book2.10


EPS (Most Recent Fiscal Year)$6.18
Net Income$211.15 million
Net Margins31.90%
Return on Equity11.33%
Return on Assets10.32%


Outstanding Shares40,100,000

The Truth About Cryptocurrencies

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its quarterly earnings results on Thursday, May, 17th. The company reported $2.17 EPS for the quarter, topping the consensus estimate of $1.51 by $0.66. The company earned $175.22 million during the quarter, compared to analyst estimates of $166.59 million. Taro Pharmaceutical Industries had a net margin of 31.90% and a return on equity of 11.33%. View Taro Pharmaceutical Industries' Earnings History.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Taro Pharmaceutical Industries.

What price target have analysts set for TARO?

1 equities research analysts have issued twelve-month price targets for Taro Pharmaceutical Industries' shares. Their predictions range from $130.00 to $130.00. On average, they anticipate Taro Pharmaceutical Industries' share price to reach $130.00 in the next twelve months. View Analyst Ratings for Taro Pharmaceutical Industries.

Who are some of Taro Pharmaceutical Industries' key competitors?

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Michael Perfetto, Group VP (Age 57)
  • Mr. Ara Aprahamian, Exec. Officer
  • Mr. Uday V. Baldota, CEO & Director (Age 48)
  • Mr. Mariano Balaguer, VP, CFO & Chief Accounting Officer (Age 45)
  • Mr. Jeff Holm, Exec. Director Sales and Operations

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

Headlines about TARO stock have been trending somewhat positive on Monday, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Taro Pharmaceutical Industries earned a news sentiment score of 0.08 on Accern's scale. They also assigned media stories about the company an impact score of 45.95 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Matthews International Capital Management LLC (0.98%), Dimensional Fund Advisors LP (0.65%), Schroder Investment Management Group (0.64%), Fort L.P. (0.44%), Freestone Capital Holdings LLC (0.42%) and Millennium Management LLC (0.26%). View Institutional Ownership Trends for Taro Pharmaceutical Industries.

Which institutional investors are selling Taro Pharmaceutical Industries stock?

TARO stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Matthews International Capital Management LLC, Aperio Group LLC, Russell Investments Group Ltd., Cubist Systematic Strategies LLC, CLARET ASSET MANAGEMENT Corp, Royal Bank of Canada and Anchor Capital Advisors LLC. View Insider Buying and Selling for Taro Pharmaceutical Industries.

Which institutional investors are buying Taro Pharmaceutical Industries stock?

TARO stock was bought by a variety of institutional investors in the last quarter, including Jupiter Asset Management Ltd., Freestone Capital Holdings LLC, Dimensional Fund Advisors LP, Seizert Capital Partners LLC, Systematic Financial Management LP, Barclays PLC, Alps Advisors Inc. and Citadel Advisors LLC. View Insider Buying and Selling for Taro Pharmaceutical Industries.

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $115.59.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $4.71 billion and generates $661.91 million in revenue each year. The company earns $211.15 million in net income (profit) each year or $6.18 on an earnings per share basis.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKTOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]

MarketBeat Community Rating for Taro Pharmaceutical Industries (TARO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.